Selective reduction of amyloid β42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid β peptide aggregation

Samankaltaisia teoksia

• Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
  Tekijä: Bibl, Mirko, et al.
  Julkaistu: (2010)
• CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
  Tekijä: Bibl, Mirko, et al.
  Julkaistu: (2006)
• Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
  Tekijä: Bibl, Mirko, et al.
  Julkaistu: (2012)
• Correction to: Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
  Tekijä: Bibl, Mirko, et al.
  Julkaistu: (2018)
• Distinctive roles of different β-amyloid 42 aggregates in modulation of synaptic functions
  Tekijä: Chiang, Hsueh-Cheng, et al.
  Julkaistu: (2009)